Drugs / Evexomostat
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02743637 | Feb 2016 → Dec 2019 | cancer, metastatic neoplasm | SynDevRx, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05455619 | Aug 2022 → Dec 2026 expected | hormone receptor-positive breast cancer | SynDevRx, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05570253 | Oct 2022 → Oct 2027 expected | triple-negative breast carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Evexomostat | “A Phase 2, Double Blinded, Randomized Controlled Trial of Evexomostat (SDX-7320) or Placebo in Combination With Eribulin for Patients With Metastatic Triple-Negative Breast...” NCT05570253 ↗ |
| Known as | Metap2 inhibitor sdx-7320 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802217 ↗ |
| Known as | SDX-7320 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05570253 ↗ |
| Action | Inhibit | “novel MetAP2 inhibitor” NCT02743637 ↗ |
| Modality | Other / unclassified | “synthetic copolymer-drug conjugate” NCT02743637 ↗ |
| Route | Subcutaneous | “subcutaneously administered SDX-7320” NCT02743637 ↗ |
| Target | METAP2 | “a novel MetAP2 inhibitor” NCT05455619 ↗ |